Aura Biosciences, Inc. Logo

Aura Biosciences, Inc.

Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.

AURA | US

Overview

Corporate Details

ISIN(s):
US05153U1079
LEI:
Country:
United States of America
Address:
80 GUEST STREET, 2135 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing a novel class of targeted cancer therapies. The company's proprietary Virus-Like Drug Conjugate (VDC) platform uses Virus-Like Particles (VLPs) to selectively target and destroy solid tumor cells while aiming to preserve healthy tissue. Aura's initial focus is on indications with significant unmet medical needs, particularly in ocular and urologic oncology. Its lead clinical program is being evaluated as a potential first-line treatment for early-stage choroidal melanoma, a rare eye cancer where current treatments often result in vision loss.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aura Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aura Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aura Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea 475830
OSR Holdings, Inc. Logo
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America OSRH
OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America OSTX
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan 4578
Outlook Therapeutics, Inc. Logo
Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.
United States of America OTLK
Ovid Therapeutics Inc. Logo
Developing targeted small molecule therapies for rare neurological diseases and epilepsies.
United States of America OVID
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom OCTHF
Pacira BioSciences, Inc. Logo
Advancing non-opioid therapies for postsurgical, chronic, and musculoskeletal pain.
United States of America PCRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.